SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001567619-20-017861
Filing Date
2020-10-15
Accepted
2020-10-15 17:08:29
Documents
2
Period of Report
2020-10-15

Document Format Files

Seq Description Document Type Size
1 FORM 3 doc1.html 3  
1 FORM 3 doc1.xml 3 20619
2 poa_beigelman.htm EX-24 8564
  Complete submission text file 0001567619-20-017861.txt   30602
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Issuer) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O ALIGOS THERAPEUTICS, INC. ONE CORPORATE DRIVE, 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address
Beigelman Leonid (Reporting) CIK: 0001824721 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39617 | Film No.: 201242055